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Although therapy for upper extremity deep
venous thrombosis (UEDVT) remains controversial,
our group has chosen to treat UEDVT as aggressive-
ly as we treat lower extremity DVT (LEDVT). This
approach is supported by the incidence of pulmonary
embolism (PE) ranging from 4% to 28% in patients
with UEDVT, which it makes it comparable to that of
LEDVT.1-8 Consequently, we have tried to systemi-
cally anticoagulate these patients with UEDVT by
means of a full course of heparin and warfarin.
However, treatment for those patients found to have
an UEDVT who have contraindications to anticoagu-
lation or who have a PE despite adequate anticoagu-
lation has not well been addressed in the literature.
We propose that these patients would benefit from
the placement of a superior vena cava (SVC) filter.9-13
Our previously reported experience with SVC fil-
ters demonstrated the clinical feasibility of the place-
ment of filters in the SVC. Nevertheless, there is
scant follow-up in the literature examining a large
series of patients undergoing placement of SVC fil-
ters. Issues concerning long-term efficacy, SVC
thrombosis, migration of the filter, and perforation
of the SVC have not been addressed. On the basis of
our recent experience, we discuss the values and lim-
itations of the placement of SVC filtration devices in
the acute setting. 
PATIENTS AND METHODS
From July 1993 to January 2000, there were
2232 upper extremity venous duplex scans per-
formed to rule out UEDVT at our institution, which
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is accredited by the Intersocietal Commission for the
Accreditation of Vascular Laboratories. We diag-
nosed UEDVT in 293 (8.6%) of these patients.
During this time period, we placed SVC filters in 72
(24.5%) patients with UEDVT in whom anticoagu-
lation was either deemed contraindicated (n = 67) or
proved ineffective in preventing recurrent PE or
extension of the thrombus (n = 5). Of the remaining
221 patients with UEDVT, 28 patients did not
receive anticoagulation. Of these, eight (29%) died
within 2 months of the diagnosis of DVT. None had
clinical evidence of PE. During the same time peri-
od, 2107 (10%) of the 20,542 lower extremity
duplex scans performed at our institution were pos-
itive for acute LEDVT. We placed 683 inferior vena
cava (IVC) filters in these patients (30%). 
Of the 72 patients with SVC filters, there were
25 (35%) men. The ages of these 72 patients ranged
from 25 to 99 years (mean, 74 ± 1.7 years [SEM]).
Nineteen (26%) patients had a malignancy, 20 (28%)
had central venous catheters, and 1 (1%) patient had
systemic lupus erythematosus. The remaining 25
patients had no identifiable risk factors. Nineteen
(26%) patients had UEDVTs involving the left side,
48 (67%) UEDVTs were on the right side, and 5
(7%) were bilateral. The most proximal extent of the
DVT was the subclavian vein in 44 (61%) patients,
the axillary vein in 13 (18%), the brachial vein in 5
(7%), and the internal jugular vein in 10 (14%).
The duplex scan examinations included visualiza-
tion of the innominate, subclavian, axillary, brachial,
internal jugular, radial, and ulnar veins. The criteria
for making the diagnosis of acute UEDVT were the
absence of spontaneous flow with either respiration
or augmentation maneuvers, inability to compress
the vein whenever applicable, and hypoechoic sig-
nals within the vein lumen. All examinations were
recorded on videotape and interpreted by attending
vascular surgeons in conjunction with registered vas-
cular technologists.
Indications for filter insertion included a con-
traindication to anticoagulation in 67 (94%) patients,
PE despite adequate anticoagulation in 2 (3%)
patients, and proximal extension of their DVT on
repeat duplex scan examination in 3 (4%) patients.
Contraindications to anticoagulation included gas-
trointestinal bleeding in 61 (86%) patients, severe
thrombocytopenia after anticoagulation in 2 (3%)
patients, thoracic aneurysm in 2 (3%) patients, brain
metastases in 1 (1%) patient, and a cerebral aneurysm
in 1 (1%) patient. All five patients with extension of
DVT or recurrent PE despite anticoagulation were
noted to have an activated partial thromboplastin
time of more than 50 seconds after diagnosis of
UEDVT. Two of these patients underwent workup
for their recurrent DVTs and were found to have
lupus anticoagulant. Two of these five patients died
within 2 months of diagnosis of UEDVT.
Acute PE was diagnosed in five (7%) of the
patients by means of high probability ventilation/per-
fusion scans or a computed tomographic scan of the
chest before placement of the SVC filter. Fifteen
patients underwent ventilation/perfusion scans that
had negative (n = 10) or intermediate (n = 5) results.
In addition, three (4%) of the 72 patients had already
undergone previous insertion of an IVC filter, and 23
(32%) other patients underwent simultaneous inser-
tion of both SVC and IVC filters because concomi-
tant UEDVT and LEDVT.10
After venous access patency was determined by
means of duplex scan examination, an intraoperative
superior venacavogram was performed to ensure a caval
diameter of less than 28 mm and to identify any venous
anomalies. An SVC filter was percutaneously inserted in
all patients by vascular surgeons in the operating room.
Because it is our preference, we placed 60 of the filters
using a femoral approach. Because LEDVT in the ipsi-
lateral superficial femoral vein or popliteal vein or con-
tralateral leg is not a contrainidication to placement of
the filter through the femoral vein, most of the SVC fil-
ters could be placed from a femoral approach. The
remaining 12 filters were placed through the right
internal jugular vein.
These 72 patients with SVC filters were com-
pared with 72 randomly selected age- and sex-
matched patients who underwent placement of IVC
filters during the same time period. Indications for
placement of the IVC filter included gastrointestinal
bleeding in 57 (79%) patients, failure of anticoagu-
lation to prevent PE or DVT in 7 (10%) patients,
metastatic carcinoma in 4 (6%) patients, recent hem-
orrhagic cerebral vascular accident in 3 (4%)
patients, and recent surgery in 1 (1%) patient.
Data were reviewed for all patients from medical
records, office charts, databases from the hospital
radiology department, the Social Security
Administration Death Index, the New York City
Department of Vital Statistics, telephone interviews
and clinical examination. Statistical analysis was per-
formed with χ2 analysis and the Student t test with
the Texas Soft WinKS4.21 program (Cedar, Tex) and
Graphpad Instat 2.05a program (San Diego, Calif).
RESULTS
Seventy-two SVC Greenfield filters were inserted
into 72 patients with UEDVT. Follow-up ranged
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from 10 days to 78 months (mean, 7.8 months).
Thirty-four patients (47%) died in the hospital of
causes unrelated to the SVC filter or recurrent
thromboembolism. The cause of death in these
patients appeared to be multisystem organ dysfunc-
tion including sepsis, respiratory failure, and acute
renal failure. These patients underwent prolonged
ventilatory support, dialysis, and administration of
multiple pressor agents and antibiotics. However, no
autopsies were performed on these patients. Four
additional patients died during the follow-up.
Thirteen patients had follow-up of more than 1 year.
The average interval between filter placement
and date of in-hospital death was 20 ± 6.1 (SEM)
days. Follow-up of the surviving patients ranged
from 1 month to 78 months (mean, 22 ± 2.8
[SEM] months); none of these patients were seen
with any clinical evidence of PE or SVC thrombo-
sis. One SVC filter was incorrectly discharged into
the innominate vein and left in place. This vein
remains patent 2 months after insertion without
evidence of filter migration. The other 71 (99%)
procedures were performed without complications.
Specifically, there was no evidence of procedure-
related pneumothorax, hemothorax, or arrhyth-
mias, as documented by postoperative chest radi-
ograph and intraoperative electrocardiogram mon-
itoring. Postoperatively, there were no episodes
suggestive of PE, SVC thrombosis, or perforation
of the SVC or myocardium after the SVC filter
placement in any patient. Sequential chest radi-
ographs taken for reasons other than for follow-up
of the SVC filter placement revealed no filter
migration or displacement in the 26 patients, with
a mean of 2 months after SVC filter placement
(Figure). Postoperatively, one filter was dislodged
during placement of a central line with the J-wire.
The filter remained in the innominate vein without
further sequalae. Fluoroscopy was not used during
this procedure.
Using the Fisher exact or χ2 test, we found no
significant differences in age, sex, or comorbid
medical problems (including diabetes mellitus,
hypertension, history of tobacco use, intensive care
unit [ICU] admission, localized or metastatic neo-
plasm, history of LEDVT, and in-hospital treat-
ment for infection) between patients who were dis-
charged from the hospital alive and those who had
died (Table I). Presence of a central line did reach
statistical significance between the two groups.
Table II demonstrates the various factors present in
the subgroups of patients who died. The patients
who have SVC filters are compared with the age-
and sex-matched patients with IVC filters in Table
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Example of SVC filter. Chest x-ray film in November 1995. Arrow marks SVC filter. Same patient’s
chest x-ray film in March 1997. Note no apparent change in location of filter despite three interval
placements of long-term venous catheters.
III. None of the patients had an SVC more than 28
mm in diameter.
DISCUSSION
Examination of the history of therapy for lower
extremity venous thromboembolism reveals an evo-
lution that has included various types of anticoagu-
lation and different techniques of caval interruption.
This has progressed with the basic appreciation of
the natural history of the disease process and the
effects of the interventions that may be made.
Recent data also indicate that UEDVT may be asso-
ciated with PE.8,14 Extrapolation of the data for
LEDVT has led us to the hypothesis that anticoagu-
lation may be able to prevent PE in patients with
UEDVT. However, because some of these patients
will be unable to undergo anticoagulation, alternate
treatment options need to be explored. The success-
ful clinical use of IVC filters, experimental data on
the use of SVC filters in animals, and case reports of
SVC filters placed in humans have allowed us to
report our initial experience on the safety and effica-
cy of SVC filters in patients unable to undergo anti-
coagulation.6,8,9,15,16 These preliminary data now
need additional refinement on the basis of informa-
tion gleaned from further experience.
Thirty-two percent of the patients in this series
had LEDVT. Often these cases were silent, clinical-
ly. In a separate series of 41 patients, 39% of patients
undergoing placement of an SVC filter were found
to have an LEDVT.17 When we screened patients
with UEDVT for LEDVT, we had found that 10
(38%) of the 26 patients with UEDVT had asymp-
tomatic LEDVT.10 Because of the high association
of UEDVT with LEDVT, we suggest that lower
extremity venous duplex scans be obtained preoper-
atively to assess the extent of thrombosis and to
assess the lower extremity venous system as an access
route for potential placement of an SVC/IVC filter.
Furthermore, we suggest that systemic factors may
play a role in the pathogenesis of DVT in a signifi-
cant percentage of these patients because a signifi-
cant portion of patients with UEDVT has been
found to have a hypercoagulable state.18,19
One of the most striking features of this series
was the extremely high mortality rate in these
patients. Similarly, an earlier report found a survival
rate of only 48% at 6 months.14 Although it is diffi-
cult to analyze the factors contributing to the high
mortality rate associated with UEDVT, in an earlier
review of patients with UEDVT,11 we concluded
that clinically evident PE did not seem to contribute
to this high mortality rate, whereas the underlying
severity of the comorbid medical problems (eg, mul-
tiorgan system dysfunction, sepsis, metastatic carci-
noma) may play a role in these findings.
Analysis of this mortality rate suggested that the
patients with central lines did have the highest mor-
tality rates. This may have been partially due to the
underlying comorbidities that necessitated the place-
ment of the central line. However, this analysis failed
to identify a subset of the population with a limited
life expectancy in whom the SVC filter placement
would have little benefit. This may have been a
result of the relatively small number of patients in
each subgroup. Because of the difficulty in justifying
placement of an SVC filter in a moribund patient
and appreciating the high mortality rate associated
with UEDVT, we have attempted to limit the use of
SVC filters to patients with an expected life
expectancy greater than 1 month, fully realizing that
prediction of life expectancy by any measure can be
extremely inaccurate. These retrospective data sug-
gest that the elderly patients with multiple comorbid
factors with multiorgan system dysfunction (eg,
acute respiratory failure, cardiogenic shock, fulmi-
nant sepsis, and acute renal failure) at the end of a
protracted intensive care stay would be the type of
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Table I. Differences between in-hospital deaths and patients alive at discharge
Nonsurvivors (%) Survivors (%) P value
Average age (y) 77 ± 4 72 ± 2.5 .14
Males/females 15/19 (44) 11/27 (29) .22
Diabetes mellitus 2/34 (6) 8/38 (21) .09
Hypertension 8/34 (23) 11/38 (29) .79
History of tobacco use 4/34 (13) 10/38 (26) .38
History of neoplasm 9/34 (26) 10/38 (26) .60
Presence of central venous line 19/34 (56) 10/38 (26) .02
History of LEDVT 6/34 (18) 11/38 (29) .28
Concomitant LEDVT 13/34 (38) 11/38 (29) .46
Admission to ICU 9/34 (26) 7/38 (18) .57
In-hospital treatment for infection 9/34 (26) 10/38 (26) .60
patient in whom limiting the placement of an SVC
filter because of minimal expected benefit might be
considered. On the other hand, the incidence of PE
(about 8% in our experience) does not seem to cor-
relate with the site of UEDVT, placement of central
line, pacemaker, history of carcinoma, and age of the
patient. Therefore, these criteria do not seem to sug-
gest which UEDVT would be less likely to cause PE
and may not need placement of a SVC filter.8,14
When comparing these results to that of IVC fil-
ters, we noted several differences and similarities.
The higher in-hospital mortality rate of the patients
with SVC filters as compared with the patients with
IVC filters suggests that the underlying comorbid
conditions of these patients may vary. The rate of
SVC thrombosis after SVC filter placement seems to
be quite low; only two cases have been report-
ed.20,21 Whether this is due to the higher flow rates
in the SVC as compared with the IVC is unknown.
Because the SVC is a shorter vessel as compared with
the infrarenal IVC, more attention to detail is need-
ed for correct filter placement. A superior venacavo-
gram is crucial to identify the SVC and the junction
of the innominate veins to prevent placement of the
filter into the innominate veins. One might expect a
higher incidence of filter migration with SVC place-
ment because of the cardiac activity. However, no
data appear to support this hypothesis. Nevertheless,
because the follow-up for SVC filters is much short-
er and has fewer patients as compared with historical
controls for IVC filters, further confirmation from
other institutions with prospective data is needed. 
Filters have now been placed for therapeutic
occlusion of anomalous venous connections.22,23
After placement of the filter, coils have been
embolized to the filter to thrombose the duplicated
SVC. Although not identical to the situation of
thromboembolism, these cases do attest to the effi-
cacy of the SVC filter to trap large emboli.
Another concern has been the future cannulation
of the right heart. Although there have been reports
of dislodging an IVC filter with cannulation, we have
noted multiple cases of the passage of central venous
catheters, pacemakers, hemodialysis catheters, and
Swan-Ganz catheters through these SVC filters with-
out dislodging the filter. Fluoroscopy for placement
of these catheters to prevent dislodging the filter is
suggested because one case of dislodgment occurred
when fluoroscopy was not used.14,24
Insertion of an SVC filter is safe therapy to pre-
vent recurrent thromboembolism in patients with
UEDVT who are resistant to anticoagulation or who
have contraindications to anticoagulation. There
have been no major complications related to the
procedure, and a similar rate of complications to
IVC filter placement can be expected.25 On inter-
mediate follow-up, there remains no clinical evi-
dence of recurrent PE or SVC thrombosis after SVC
filter placement in our cohort of patients. Of course,
certain precautions need to be taken to avoid the
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Table II. In-hospital death rate of various subgroups
Risk factor present (%) Risk factor absent (%) P value
Age > 75 y 20/40 (50) 14/32 (44) .6
Female sex 19/46 (41) 15/26 (58) .18
Diabetes mellitus 2/10 (20) 32/62 (51) .06
Hypertension 8/19 (42) 26/53 (49) .6
History of tobacco use 4/14 (29) 30/58 (52) .12
History of neoplasm 9/19 (47) 25/53 (47) .6
Presence of central venous line 19/29 (66) 15/43 (35) .01
History of LEDVT 6/17 (35) 28/55 (51) .26
Concomitant LEDVT 13/24 21/48 .06
Admission to ICU 9/16 25/56 .4
In-hospital treatment for infection 9/19 25/53 1.0
Table III. Comparison of SVC and IVC filters
SVC filter (n = 72) IVC filter (n = 72) P value
Mean follow-up ± SEM (mo) 7.8 ± 2 10 ± 1.9 .25
In-hospital death (%) 47 12.5 < .001
Posthospital death (%) 6 43 < .001
Mean time to death ± SEM (mo) 0.7 ± 0.2 4.6 ± 0.8 < .001
pitfalls of SVC filter placement, and further data
need to be collected to properly assess which
patients are candidates for the procedure. However,
the overall efficacy and safety of filters placed in the
SVC seem to justify further investigation. 
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DISCUSSION
Dr Patricia Thorpe (Omaha, Neb). Thank you, Dr
Harris, and good morning. This study represents a very
large series of patients who underwent SVC filter place-
ment, perhaps the largest in the world. In fact, until last
year in 1999, the number of SVC filters placed in people
was equal to that placed in dogs in the experimental study
by Dr Greenfield, which was published in 1985. The series
from the Cleveland Clinic was published in 1999, just last
year, where they had 41 patients and also demonstrated
effectiveness and safety of placing an SVC filter. They only
had follow-up of 15 weeks, and therefore, the present
study with median follow-up of 22 months, for patients
who survived the hospitalization, represents an important
contribution to better understanding this area of increasing
clinical concern because of the increase in the amount of
upper extremity thrombosis associated with central line
placement. The paper emphasizes that we must not disre-
gard this upper extremity thrombosis. I think a lot of us
have thought it was relatively benign because of collateral-
ization, but particularly in patients who are not anticoagu-
lated, maybe there is a risk of pulmonary embolus.
Although pulmonary embolus may occur between 12% and
18% in some of the literature studies, absolute fatal
embolization from subclavian thrombosis is relatively rare,
probably 1% to 2% of all patients with upper extremity
thrombosis. Although your study clearly demonstrates the
technical safety of filter placement and points out the
anatomical concerns pertinent to placing an upside-down
filter in a relatively limited space, I think that your report
begs several questions, especially in the analysis, so I would
like to ask these right now.
The first question does indeed deal with patient selec-
tion. You placed SVC filters in 10% of the patients you
diagnosed with upper extremity DVT. I know that you did
preinsertion cavograms to assess the size of the cava, but
did you in fact do extremity phlebography to identify
patients who had subclavian stenoses or mediastinal com-
pression related to tumor compression, both of which
might be contraindications to filter placement? In the first
group they might be less likely to embolize with the steno-
sis in the subclavian and therefore not need a filter. In the
second group, if you already have mediastinal compres-
sion, it may be a setup for SVC thrombosis. 
You did point out that an SVC thrombosis has only
been reported twice in the literature associated with filter
placement in the SVC, and in fact, that represents almost
20% of those first 11 cases. That in itself is not benign.
The other thing associated with phlebography is, do
you think that minimal nonocclusive thrombus requires a
filter placement in the absence of anticoagulation?
You did point out that a significant number of patients
died within 20 days. In fact, a large percentage of your
patients did not survive the hospitalization. This compares
with the Cleveland study that showed almost a similar mor-
tality rate at 1 year. There was a study in 1994 presented by
the Swedish group led by Bergqvist that showed that very
few elderly patients with moribund conditions benefit from
filter placement so the group cautioned that we should be
very selective in whom we put filters and about patients
who are ICU bound at that time in their lives. 
So although your clinical follow-up appears excellent,
the study does in fact lack objective patient follow-up, which
is true of the other large study as well. We do not know how
many patients have actually had a PE or superior vena cava
perforation or occlusion, so it would be ideal to have this
information perhaps with CT scanning or echocardiography.
I understand the limitations of doing that kind of study, but
do you have any data like this or do you plan to do this in
the future, because if not I encourage you to do so.
Lastly, given your extensive experience compared with
all the rest of us in this room, would you suggest any
design modifications to make a better filter for the superi-
or vena cava when it is indeed indicated?
I compliment you on your impressive series. I want to
thank you for giving me your manuscript in advance. It is
a privilege to be asked to be a discussant for this paper.
Thank you.
Dr Enrico Ascher. Thank you very much, Dr Thorpe.
Yes, the patient selection of these patients undergoing this
type of therapy is a very thorny issue. Initially, we really
were placing them in just about any patient with an upper
extremity DVT and contraindication to anticoagulation,
but as we accumulated the data from the upper extremity
DVT patients and from the SVC filter patients, we realized
that we need to be more selective, just because the mortal-
ity rate was ridiculous and it did not make sense to be plac-
ing this type of filter in patients who really did not have a
1-month survival. 
As I said, we tried to limit, being more selective in
placement of these types of filter in a moribund who is real-
ly not going to make it out of the hospital; however, that is
a very subjective criteria. When we tried to analyze some of
these things, again as we tried to look at APACHE scores
or injury severity scores, trying to predict which patients—
when you really look at those papers there is always going
to be a patient who has a high expectation who does not
make it out of the ICU—the 90-year-old who is in septic
shock with multiorgan system dysfunction is going to make
it. They always end up making the studies much more dif-
ficult in trying to predict which patients are not going to
make it, so while we have tried to be more selective and we
do agree that you do have to be selective in this type of
patient population, it can be a very thorny issue.
We do perform vena cavograms on all of the patients,
but we do not perform upper extremity phlebography. The
only time that we usually would try to do that would be if
a patient clinically had a history of thoracic outlet syn-
drome. We have only had two patients who fit into that cat-
egory who underwent thoracic outlet decompression in
our prior series, which covered about 6 years. That I think
has to be treated very differently. Most of these types of
patients who presented for the SVC filters seem to be a dif-
ferent type of patient. They seem to be much older, and
most of them were quite sick and in the intensive care unit.
The issue of nonocclusive DVTs with the upper extrem-
ity is very difficult. There is really very little literature sug-
gesting what the incidence of PEs is with even lower extrem-
ity nonocclusive and what the natural history of nonocclusive
lower extremity or upper extremity DVTs is. Because of the
lack of data, we have really been treating them with full anti-
coagulation and placement of an SVC filter if indicated.
With regard to some of the changes that we would sug-
gest in design modification. The Cleveland Clinic has also
suggested that there need to be some changes made in terms
of smaller foot size, and perhaps a smaller length of the filter.
However, while these issues are being looked into, we are
still talking about a relatively small number of patients. When
we had 72 patients, we had almost 10 times that number of
patients who had placement of an IVC filter. So the number
of patients who are going to be undergoing this type of pro-
cedure also needs to be taken into consideration.
Thank you.
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